The initial order of $406,200 includes six SKUs (stock-keeping units) of 2.5 mg THC, 5.0 mg THC, 12.5 mg CBD, 25 mg THC and two caplets with 5.0 mg THC/25 mg CBD and 2.5 mg THC/12.5 mg CBD, respectively. The week that was offered a mix of happenings, from advancing diversity to shedding jobs, identifying why weed smells like weed and getting all excited about exports. It is anticipated that Cann Global will make some of the Canntab products available to the Cannabinoid Medicine Observational Study, notes Canntab CEO Larry Latowsky. Australia’s largest observational medical weed study aims to collect data from 20,000 people nationwide to assess the safety and efficacy of cannabis products for conditions such as fibromyalgia, chronic pain syndromes, post-traumatic stress disorder and epilepsy. Citing an industry in transition and a nationwide excess supply of weed, the streamlining seeks to further improve margins, bolster efficiencies and advance sustainable growth, reports the vertically integrated licensed producer (LP).
The week that was offered a mix of happenings, from advancing diversity to shedding jobs, identifying why weed smells like weed and getting all excited about exports.
Righting wrongs, advancing research and finding the right person for the job Happy dancing, double checking, going Dutchie and the (weed tax) revenue keeps rolling in Up...Read the full article @ The Growth Op